@article{TamihardjaLawrenzLutyjetal.2022,
  author    = {Tamihardja, J{\"o}rg and Lawrenz, Ingulf and Lutyj, Paul and Weick, Stefan and Guckenberger, Matthias and Polat, B{\"u}lent and Flentje, Michael},
  title     = {Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer},
  series = {Strahlentherapie und Onkologie},
  volume    = {198},
  journal   = {Strahlentherapie und Onkologie},
  number    = {8},
  doi       = {10.1007/s00066-022-01953-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325055},
  pages     = {735-743},
  year      = {2022},
  abstract  = {Purpose Dose-escalated external beam radiation therapy (EBRT) and EBRT + high-dose-rate brachytherapy (HDR-BT) boost are guideline-recommended treatment options for localized prostate cancer. The purpose of this study was to compare long-term outcome and toxicity of dose-escalated EBRT versus EBRT + HDR-BT boost. Methods From 2002 to 2019, 744 consecutive patients received either EBRT or EBRT + HDR-BT boost, of whom 516 patients were propensity score matched. Median follow-up was 95.3 months. Cone beam CT image-guided EBRT consisted of 33 fractions of intensity-modulated radiation therapy with simultaneous integrated boost up to 76.23 Gy (D\(_{Mean}\)). Combined treatment was delivered as 46 Gy (D\(_{Mean}\)) EBRT, followed by two fractions HDR-BT boost with 9 Gy (D\(_{90\\%}\)). Propensity score matching was applied before analysis of the primary endpoint, estimated 10-year biochemical relapse-free survival (bRFS), and the secondary endpoints metastasis-free survival (MFS) and overall survival (OS). Prognostic parameters were analyzed by Cox proportional hazard modelling. Genitourinary (GU)/gastrointestinal (GI) toxicity evaluation used the Common Toxicity Criteria for Adverse Events (v5.0). Results The estimated 10-year bRFS was 82.0\% vs. 76.4\% (p = 0.075) for EBRT alone versus combined treatment, respectively. The estimated 10-year MFS was 82.9\% vs. 87.0\% (p = 0.195) and the 10-year OS was 65.7\% vs. 68.9\% (p = 0.303), respectively. Cumulative 5‑year late GU ≥ grade 2 toxicities were seen in 23.6\% vs. 19.2\% (p = 0.086) and 5‑year late GI ≥ grade 2 toxicities in 11.1\% vs. 5.0\% of the patients (p = 0.002); cumulative 5‑year late grade 3 GU toxicity occurred in 4.2\% vs. 3.6\% (p = 0.401) and GI toxicity in 1.0\% vs. 0.3\% (p = 0.249), respectively. Conclusion Both treatment groups showed excellent long-term outcomes with low rates of severe toxicity.},
  language  = {en}
}
@article{TamihardjaSchortmannLawrenzetal.2021,
  author    = {Tamihardja, J{\"o}rg and Schortmann, Max and Lawrenz, Ingulf and Weick, Stefan and Bratengeier, Klaus and Flentje, Michael and Guckenberger, Matthias and Polat, B{\"u}lent},
  title     = {Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis},
  series = {Strahlentherapie und Onkologie},
  volume    = {197},
  journal   = {Strahlentherapie und Onkologie},
  issn      = {0179-7158},
  doi       = {10.1007/s00066-020-01678-w},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-232509},
  pages     = {124-132},
  year      = {2021},
  abstract  = {Purpose Evaluation of long-term outcome and toxicity of moderately hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost treatment planning and cone beam CT-based image guidance for localized prostate cancer. Methods Between 2005 and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy using cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modulated arc therapy (IG-VMAT) with a simultaneous integrated boost (SIB). Total doses of 73.9 Gy (n = 44) and 76.2 Gy (n = 302) to the high-dose PTV were delivered in 32 and 33 fractions, respectively. The low-dose PTV received a dose (D95) of 60.06 Gy in single doses of 1.82 Gy. The pelvic lymph nodes were treated in 91 high-risk patients to 45.5 Gy (D95). Results Median follow-up was 61.8 months. The 5‑year biochemical relapse-free survival (bRFS) was 85.4\% for all patients and 93.3, 87.4, and 79.4\% for low-, intermediate-, and high-risk disease, respectively. The 5‑year prostate cancer-specific survival (PSS) was 94.8\% for all patients and 98.7, 98.9, 89.3\% for low-, intermediate-, and high-risk disease, respectively. The 5‑year and 10-year overall survival rates were 83.8 and 66.3\% and the 5‑year and 10-year freedom from distant metastasis rates were 92.2 and 88.0\%, respectively. Cumulative 5‑year late GU toxicity and late GI toxicity grade ≥2 was observed in 26.3 and 12.1\% of the patients, respectively. Cumulative 5‑year late grade 3 GU/GI toxicity occurred in 4.0/1.2\%. Conclusion Moderately hypofractionated radiotherapy using SIB treatment planning and cone beam CT image guidance resulted in high biochemical control and survival with low rates of late toxicity.},
  language  = {en}
}
@article{HardcastleTomeCannonetal.2012,
  author    = {Hardcastle, Nicholas and Tom{\´e}, Wolfgang A. and Cannon, Donald M. and Brouwer, Charlotte L. and Wittendorp, Paul W. H. and Dogan, Nesrin and Guckenberger, Matthias and Allaire, St{\´e}phane and Mallya, Yogish and Kumar, Prashant and Oechsner, Markus and Richter, Anne and Song, Shiyu and Myers, Michael and Polat, B{\"u}lent and Bzdusek, Karl},
  title     = {A multi-institution evaluation of deformable image registration algorithms for automatic organ delineation in adaptive head and neck radiotherapy},
  series = {Radiation Oncology},
  volume    = {7},
  journal   = {Radiation Oncology},
  number    = {90},
  doi       = {10.1186/1748-717X-7-90},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134756},
  year      = {2012},
  abstract  = {Background: Adaptive Radiotherapy aims to identify anatomical deviations during a radiotherapy course and modify the treatment plan to maintain treatment objectives. This requires regions of interest (ROIs) to be defined using the most recent imaging data. This study investigates the clinical utility of using deformable image registration (DIR) to automatically propagate ROIs. Methods: Target (GTV) and organ-at-risk (OAR) ROIs were non-rigidly propagated from a planning CT scan to a per-treatment CT scan for 22 patients. Propagated ROIs were quantitatively compared with expert physician-drawn ROIs on the per-treatment scan using Dice scores and mean slicewise Hausdorff distances, and center of mass distances for GTVs. The propagated ROIs were qualitatively examined by experts and scored based on their clinical utility. Results: Good agreement between the DIR-propagated ROIs and expert-drawn ROIs was observed based on the metrics used. 94\% of all ROIs generated using DIR were scored as being clinically useful, requiring minimal or no edits. However, 27\% (12/44) of the GTVs required major edits. Conclusion: DIR was successfully used on 22 patients to propagate target and OAR structures for ART with good anatomical agreement for OARs. It is recommended that propagated target structures be thoroughly reviewed by the treating physician.},
  language  = {en}
}